Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jashin Wu

Dermatology Corona, CA Medical Doctor

NPI 1407953102 CMS profile 336436

760 Washburn Ave Ste 201, Corona, CA 92882

Open in the dashboard

General payments

$2,019,088

1,654 records reported · program years 2019–2025

Research payments

$46,024

Paid to them · 46 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$243,873 paid to institutions, not to them · program years 2019–2022

Through program year 2025, Jashin Wu of Corona, CA is reported in the CMS Open Payments database as having received $2,019,088 across 1,654 general payments and $46,024 in research payments paid to them. Separately, studies naming them as principal investigator received $243,873 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $138,681 124
2024 General $82,851 105
2023 General $63,500 118
2022 General $485,253 202
2022 Research $5,555 7
2021 General $231,387 98
2021 Research $14,862 23
2020 General $127,916 126
2020 Research $10,267 10
2019 General $889,500 881
2019 Research $15,339 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jashin Wu
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Jashin Wu were reported at $138,681. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Jashin Wu Dermatology median Middle half National median
2019 $889,500 $454 $129–$1,240 $163
2020 $127,916 $235 $81–$756 $114
2021 $231,387 $377 $108–$1,108 $132
2022 $485,253 $514 $143–$1,391 $149
2023 $63,500 $607 $159–$1,674 $160
2024 $82,851 $751 $204–$1,903 $164
2025 $138,681 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $672,868 209 payments
  2. Sun Pharmaceutical Industries Inc. $303,609 249 payments
  3. Amgen Inc. $140,379 121 payments
  4. Celgene Corporation $131,501 100 payments
  5. Novartis Pharmaceuticals Corporation $113,553 136 payments
  6. Regeneron Healthcare Solutions, Inc. $105,140 116 payments
  7. E.R. Squibb & Sons, L.L.C. $86,708 97 payments
  8. Ortho Dermatologics, a division of Bausch Health US, LLC $65,848 93 payments
  9. UCB, Inc. $57,046 103 payments
  10. Pfizer Inc. $56,807 26 payments
  11. Other $285,628 404 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $693,894 176 payments
  2. Grant $527,800 13 payments
  3. Consulting Fee $285,966 137 payments
  4. Honoraria $236,631 48 payments
  5. Travel and Lodging $155,178 451 payments
  6. Food and Beverage $55,388 797 payments
  7. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $50,600 12 payments
  8. Education $13,631 20 payments
Products named General payments · program years 2019–2025
  1. SKYRIZI Immunology $492,982 127 payments
  2. ILUMYA $294,589 237 payments
  3. Otezla Inflammation $130,277 116 payments
  4. Otezla Dermatology $128,547 97 payments
  5. COSENTYX $89,479 86 payments
  6. SKYRIZI Immunology $72,320 6 payments
  7. DUPIXENT Inflammation And Immunology $57,607 70 payments
  8. RINVOQ $57,563 13 payments
  9. DUPIXENT Immunology $46,812 33 payments
  10. HUMIRA $45,773 56 payments
  11. Other $336,886 612 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Amgen Inc. $11,464 3 payments
  2. Regeneron Pharmaceuticals, Inc. $11,309 23 payments
  3. Pfizer Inc. $9,940 8 payments
  4. Novartis Pharmaceuticals Corporation $8,597 4 payments
  5. UCB, Inc. $1,640 4 payments
  6. Genzyme Corporation $1,250 1 payment
  7. Celgene Corporation $1,144 1 payment
  8. Janssen Research & Development, LLC $680 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

41

Median for Dermatology: 534

Drug cost

$1,112

Median for Dermatology: $67,151

Branded share of claims

0%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Fluocinonide Generic 29 $662
Tacrolimus Generic 12 $450

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
$9,271 — —
Bimzelx
$917 — —
SOTYKTU
$671 — —
SPEVIGO
$644 — —
CIBINQO
$525 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

1,700 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record